Containment
OEB 4 Containment CDMOs
Compare CDMOs with OEB 4 containment capabilities (1-10 µg/m³ occupational exposure limit) for potent API synthesis and drug product manufacturing.
369 companies listed
About OEB 4 Containment
OEB 4 (Occupational Exposure Band 4) containment maintains airborne exposure below 1-10 micrograms per cubic meter. This level is required for many oncology APIs, hormonal drugs, and targeted small molecules with significant pharmacological activity at low doses. Engineering controls include containment isolators, high-containment dispensing booths, split-butterfly valves, and validated cleaning procedures.
OEB 4 is the most commonly requested containment level in CDMO outsourcing. Many new chemical entities in oncology and targeted therapy pipelines fall into this exposure band. CDMOs with OEB 4 capability can handle the majority of potent compound programs without the additional capital investment required for OEB 5 facilities.
Companies (369)
Adelco SA
Greece
Adelco SA is a pharmaceutical CDMO offering comprehensive services.
Oral Solid DoseSolid Dose ManufacturingFormulation Development
Algae Products International Ltd
Qatar
Algae Products International Ltd is a pharmaceutical CDMO offering comprehensive services.
Oral Solid DoseSolid Dose ManufacturingFormulation Development
Frequently Asked Questions
What is the difference between OEB 4 and OEB 5?+
OEB 4 containment maintains exposure below 1-10 µg/m³. OEB 5 maintains exposure below 1 µg/m³ (and sometimes below 0.1 µg/m³). OEB 5 requires more stringent engineering controls: fully enclosed processes, negative pressure cascades, multi-stage HEPA filtration, and rigorous decontamination procedures. OEB 4 can often use contained dispensing with downflow booths and barrier isolators, while OEB 5 typically requires full process containment from dispensing through packaging.
What types of compounds require OEB 4 containment?+
Compounds requiring OEB 4 include: many kinase inhibitors (oncology small molecules), hormonal APIs (estrogens, progestins, corticosteroids), certain immunosuppressants, and other highly pharmacologically active compounds. The OEL is determined by toxicology data and pharmacological potency. CDMOs should have toxicologists on staff or under contract to evaluate compound-specific containment requirements.
Need help finding the right CDMO?
Our AI Matchmaker analyzes your project requirements and matches you with qualified manufacturing partners. Free for buyers.
